My watch list
my.bionity.com  
Login  

3 Current news of Actelion

rss
matching the following criteria

Actelion: CONSCIOUS-2 study with clazosentan does not meet primary endpoint

28-09-2010

Actelion Ltd announced the initial results of CONSCIOUS-2 a clinical study evaluating the safety and efficacy of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in clipped patients following aneurysmal subarachnoid hemorrhage (aSAH). The primary endpoint showed a ...

more

BUILD-3 study with bosentan in idiopathic pulmonary fibrosis does not meet primary endpoint

02-03-2010

Actelion Ltd announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favor of bosentan, the primary endpoint, reduction in morbidity/mortality, was ...

more

Positive study with Actelion's bosentan (Tracleer®) in CTEPH

06-03-2007

Actelion Ltd announced the initial results from the double-blind, placebo-controlled, multicenter study BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension). The study met its primary objective, as treatment with bosentan (Tracleer®) was associated with ...

more

Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE